|  | Groups |  | P |
---|---|---|---|---|
A group (n = 89) | B group(n = 108) | |||
Age (years) | 47.66 ± 12.10 | 43.85 ± 13.76 | 0.043# | |
Gender (female) | 79 (88.8%) | 75 (69.4%) | 0.003â–² | |
Hashimoto’s disease | 18 (20.2%) | 20 (18.5%) | 0.763▲ | |
Goiter | 50 (56.2%) | 57 (52.8%) | 0.633â–² | |
T stage | ||||
 T1 | 63 (70.8%) | 65 (60.2%) | ||
 T2 | 7 (7.9%) | 14 (13.0%) | ||
 T3 | 17 (19.1%) | 23 (21.3%) | ||
 T4 | 2 (2.2%) |  | 6 (5.6%) | 0.133* |
CND range | ||||
 Unilateral CND | 58 (65.2%) | 61 (56.5%) | ||
 Bilateral CND | 31 (34.8%) | 47 (43.5%) | 0.243▲ | |
Lymph nodes retrieved | ||||
 Unilateral CND | 9.03 ± 4.701 |  | 10.67 ± 4.668 | 0.059# |
 Bilateral CND | 14.55 ± 8.045 | 15.23 ± 7.035 | 0.692# | |
 Ratio of metastasis | 43 (48.3%) | 77 (71.3%) | 0.001▲ | |
 Ratio of IPTX | 11 (12.4%) | 8 (7.4%) | 0.241▲ | |
 Ratio of AIPGS | 18 (20.2%) | 11 (10.2%) | 0.048▲ | |
 Pre-PTH (pg/ml) | 43.40 (34.90,58.75) | 43.80 (33.83,60.35) | 0.835 | |
 Pre-Ca (mmol/L) | 2.31 (2.23,2.38) | 2.32 (2.25,2.39) | 0.424 | |
Postoperative complications | ||||
 Hemorrhage | 1 (1.1%) | 2 (1.9%) | 1.000▲ | |
 Incision infection | 1 (1.1%) | 1 (1.1%) | 1.000▲ | |
 Transient RLN injury | 2 (2.2%) | 3 (2.8%) | 1.000▲ | |
 Permanent RLN injury | 1 (1.1%) | 1 (0.9%) | 1.000▲ | |
Postoperative hospital stay | 5.20 (± 3.28) | 5.26 (± 2.08) | 0.892# |